Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07327788RecruitingPhase 2
Study of QL1706, bevacizumab, and chemo infusion for liver cancer with portal vein clot
This trial tests a combination of three treatments for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this therapy can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07137910RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
Beijing, Beijing MunicipalityAges 18–65 - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT07096193RecruitingPhase 1/Phase 2
Study of GS-4321 for chronic hepatitis delta
This trial tests a new drug, GS-4321, for people with chronic hepatitis delta, a serious liver infection. It aims to see if the drug is safe and effective, and compares results in healthy volunteers and those with the virus.
Anaheim, CaliforniaAges 18–69 - NCT07046429Recruiting
Melatonin for sleep and brain health in cirrhosis
This study tests whether melatonin (a natural sleep hormone) can improve sleep and thinking abilities in people with cirrhosis and liver-related brain fog. It aims to see if better sleep leads to clearer thinking.
New York, New YorkAges 18 years+ - NCT07635186RecruitingPhase 2
AHB-137 injection for treatment-naïve chronic hepatitis B
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07428538RecruitingPhase 3
Testing larsucosterol for severe alcohol-related hepatitis
This trial tests a new medicine called larsucosterol to see if it helps people with severe alcohol-related hepatitis (liver inflammation from heavy drinking). If you qualify, the study will monitor your safety and recovery over 90 days.
Birmingham, AlabamaAges 18 years+ - NCT06092333RecruitingPhase 2
New combo therapy for chronic hepatitis B
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
Bethesda, MarylandAges 18–65 - NCT07630727RecruitingPhase 2
AHB-171 treatment for chronic hepatitis B
This study tests whether a new drug called AHB-171 can help treat chronic hepatitis B (a long-term liver infection). You would receive the drug by injection under your skin and be monitored to see if it helps reduce the hepatitis B virus and improves liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07511218RecruitingPhase 1
Study of AHB-171 for stable chronic hepatitis B
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Ch’ang-ch’un, JilinAges 18–65 - NCT07709520RecruitingPhase 2
Testing a new hepatitis B treatment in adults
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
BeijingAges 35–65 - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT03025074Recruiting
Blood sample bank for liver disease research
This study collects blood samples to build a “biobank” (a stored library of samples) for researchers studying liver diseases like hepatitis, fatty liver disease, and liver cancer. It may help future testing and treatments by allowing scientists to study patterns in people with and without liver conditions.
Buffalo, New YorkAges 7 years+ - NCT03200379Recruiting
Taiwan registry for people treated for hepatitis C
This registry is for people in Taiwan who have received direct-acting antiviral (DAA) treatment for hepatitis C. It collects health information to better understand outcomes and care, and you can join if you agree to participate and sign consent.
Kaohsiung CityAges Any age - NCT03685045Recruiting
Hepatitis C treatment support for people using opioid substitutes
This trial is studying hepatitis C treatment approaches for adults who have a history of injecting drugs, especially those who have injected recently or are on opioid substitution therapy. If you fit the background criteria, the study may offer a treatment pathway and extra support to help you get hepatitis C treated.
Canberra, Australian Capital TerritoryAges 18 years+ - NCT03825458Recruiting
Study tracking hepatitis B viral RNA in blood
This study builds a group of people to measure small hepatitis B “viral RNA” signals in the blood. The goal is to see if these measurements could help researchers find a functional cure and better understand who may respond over time.
LyonAges 18 years+ - NCT03826433RecruitingPhase 1
Study stem cell treatment for worsening hepatitis B cirrhosis
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
Changsha, HunanAges 18–60 - NCT04025944Recruiting
Study of long-term hepatitis B or C infection
This study looks at people with hepatitis B or C infections that have lasted more than 6 months. It aims to better understand long-term management and how treatments may help over time.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04073290RecruitingPhase 4
Rifaximin and lactulose to prevent confusion after TIPS
This trial studies whether taking rifaximin plus lactulose can prevent a brain problem called hepatic encephalopathy (confusion) after TIPS, a procedure to reduce pressure in the liver. It may help people who are having TIPS planned and are at risk of this complication.
LeuvenAges 18–80 - NCT04088370Recruiting
Testing blood immune cell response in alcohol-related liver disease
This study looks at how immune cells in the blood respond in people with alcoholic hepatitis and in people who drink heavily (with no known liver disease). It may help researchers understand why liver inflammation happens after heavy alcohol use.
Cleveland, OhioAges 21–65 - NCT04096014Recruiting
Protein supplement at night to prevent repeat brain episodes
This study tests whether taking extra protein in the late evening or early morning can lower the chance of being readmitted for hepatic encephalopathy, a brain problem that can happen with liver disease. It may help by supporting safer nutrition and reducing the risk of another hospitalization.
Cleveland, OhioAges 18–75 - NCT04106518Recruiting
Genetics study of alcohol-related liver disease and cirrhosis
This study looks at genetic differences in people with alcohol-related liver illness, including a recent jaundice episode (alcoholic hepatitis). By following people over time, it may help doctors better predict illness and understand why some people develop worse liver problems.
AngersAges 18 years+ - NCT04161053RecruitingPhase 3
Nitazoxanide to prevent repeat liver brain episodes
This Phase 3 trial tests whether nitazoxanide can help stop hepatic encephalopathy (a “liver-to-brain” confusion problem) from coming back. It’s for adults with cirrhosis who have had at least one past episode, aiming to improve safety and prevent recurrence.
TantaAges 20–65 - NCT04310787Recruiting
Tracking outcomes in adults with hepatitis B liver failure
This study looks at long-term survival in people ages 18–65 who are hospitalized with hepatitis B–related acute-on-chronic liver failure. It may help doctors better predict prognosis and improve care for people with this serious condition.
Guangzhou, GuangdongAges 18–65
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 484 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.